Cellectis Posts $101.1M Nine-Month Loss, Books $26.8M Impairment on Pivot
CLLS sits 51% above its 52-week low of $0.881 on light trading volume (0.4× avg).
Summary
Cellectis' Q3 interim report quantifies the September pivot: a $26.8 million impairment and $6.1 million of severance pushed the nine-month net loss to $101.1 million, while $146.5 million of cash and deposits is said to fund operations into the second half of 2028.
Key Events · Earnings and Guidance · CLLS
-
Nine-Month Loss Widens to $101.1M
Net loss for the nine months ended September 30, 2026 was $101.1 million versus $41.3 million a year earlier, and revenue fell 76.4% to $14.8 million as AstraZeneca research activity slowed.
-
Pivot Costs $26.8M Impairment Plus Severance
The strategic transformation produced a $26.8 million impairment on Raleigh and Paris assets ($2.1 million right-of-use, $24.8 million property, plant and equipment) and $6.1 million of severance provisions, with headcount expected to fall by up to 70%.
-
Cibus Lease Guarantee Becomes $9.2M Liability
After NGCRE sued Cibus and Cellectis on September 9, 2026, the company booked a $9.4 million expected credit loss and carries a $9.2 million financial guarantee liability against an $18.8 million potential undiscounted exposure.
-
Runway Stated Into Second Half of 2028
Cash and cash equivalents of $28.2 million plus $118.3 million of fixed-term deposits at September 30, 2026 are expected to fund operations into the second half of 2028 once the realignment is complete.
Analysis · CLLS · Life Sciences
The September pivot now carries a price tag: a $26.8 million write-down of the Raleigh and Paris facilities, $6.1 million of severance provisions, and a headcount cut of up to 70%. Those charges drove the nine-month net loss to $101.1 million from $41.3 million a year earlier, while revenue fell 76.4% to $14.8 million as AstraZeneca collaboration work slowed. Partly offsetting is a $9.4 million expected credit loss on the legacy Calyxt/Cibus lease guarantee, now a $9.2 million liability after the landlord sued in September. For the thesis, runway is what matters: $28.2 million of cash plus $118.3 million of fixed-term deposits is stated to fund operations into the second half of 2028, buying time for .HEAL-101 and .HEAL-201 without an immediate raise.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLLS was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.3M. The 52-week trading range was $0.88 to $5.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.